ReviewAmerican journal of clinical dermatology2024
Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.
Review in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ocular outcomes of amniotic membrane transplantation in acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review.International ophthalmology · 2026Pooled it
- When Infection and Drug Hypersensitivity Converge: An SJS-Like Mucocutaneous Reaction.International journal of dermatology · 2026Article
- SCORTEN in Contrast: Two Cases of SJS/TEN Overlap With Divergent Outcomes Highlighting the Role of Renal Dysfunction.Clinical case reports · 2026Article
- Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap With Severe Ocular and Oral Involvement: A Pediatric Case Report From Uganda.Clinical case reports · 2026Article
- Article
- Case report: Delayed onset rash, delirium, and cross allergic reactions caused by sequential administration of cefoperazone sulbactam, meropenem, and piperacillin tazobactam.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Toxic Epidermal Necrolysis Mimicking Severe Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Diagnostic Challenge.Journal of clinical medicine · 2026Article
- Immunological Interplay at the Ocular Surface of Stevens-Johnson Syndrome, Ocular Cicatricial Pemphigoid, and Ocular Graft Versus Host Disease.Investigative ophthalmology & visual science · 2026Review
- Seen on screen, missed in clinic: educational pearls fromSkin health and disease · 2026Review
- Just the facts: diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.CJEM · 2026Article
- Article
- A Pediatric Case of Stevens-Johnson Syndrome With Extensive Palmoplantar Involvement Following Varicella Infection.Cureus · 2026Article
- Trimethoprim/Sulfamethoxazole-Induced Systemic Toxic Epidermal Necrolysis Syndrome: A Case Report.Clinical case reports · 2026Article
- Article
- Stevens-Johnson syndrome and toxic epidermal necrolysis in pregnancy.The British journal of dermatology · 2026Article
- Toxic epidermal necrolysis in a preschooler associated with adenovirus respiratory infection: A case report.JAAD case reports · 2026Article
- Evaluation of drug causality in SJS/TEN: The role of the lymphocyte transformation test and conventional/modified IFN-γ ELISpot assays.The World Allergy Organization journal · 2026Article
- A Case of Toxic Epidermal Necrolysis-Like Dermatosis Associated With Contact Exposure to a Flurbiprofen Plaster.Cureus · 2026Article
- Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.International journal of clinical pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment. Significant progress has been made in understanding its genetic predisposition and pathogenesis. This review is intended to provide physicians with a comprehensive but practical SJS/TEN roadmap to guide diagnosis and management. We review data on pathogenesis, reported precipitating factors, presentation, diagnosis, and management SJS/TEN focusing on what is new over the last 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.